Efficacy of tildrakizumab for moderate-to-severe plaque psoriasis: Pooled analysis of 3 randomized controlled trials at weeks 12 and 28
Journal of the European Academy of Dermatology and Venereology | Mar 10, 2019
Journal of the European Academy of Dermatology and Venereology | Mar 10, 2019